Suchergebnisse - "Wang, Chen"

PubPharm (5)

1

Breakthrough infection elicits hypermutated IGHV3-53/3-66 public antibodies with broad and potent neutralizing activity against SARS-CoV-2 variants including the emerging EG.5 lineages

enthalten in: PLoS pathogens | 2023

von Li, L. | Chen, X. | Wang, Z. | +4

2

Safety, tolerability, and immunogenicity of a CpG/Alum adjuvanted SARS-CoV-2 recombinant protein vaccine (ZR202-CoV) in healthy adults : Preliminary report of a phase 1, randomized, double-blind, placebo-controlled, dose-escalation trial

enthalten in: Human vaccines & immunotherapeutics | 2023

von Feng, G. | Wang, Z. | He, P. | +21

3

Humoral responses after inactivated COVID-19 vaccination in individuals with and without prior SARS-CoV-2 infection : A prospective cohort study

enthalten in: Journal of medical virology | 2022

von Jia, M. | Wang, X. | Gong, W. | +25

4

Seroprevalence and dynamics of anti-SARS-CoV-2 antibodies : a longitudinal study based on patients with underlying diseases in Wuhan

enthalten in: Respiratory research | 2022

von Yang, J. | Ma, L. | Guo, L. | +12

ErratumIn: Respir Res. 2022 Aug 25;23(1):218. - PMID 36008840

5

Seroprevalence and humoral immune durability of anti-SARS-CoV-2 antibodies in Wuhan, China : a longitudinal, population-level, cross-sectional study

enthalten in: Lancet (London, England) | 2021

von He, Z. | Ren, L. | Yang, J. | +27

CommentIn: Lancet. 2021 Mar 20;397(10279):1037-1039. - PMID 33743854

1
[1]